SHR6390 Tablets + Placebo Tablets + Letrozole or Anastrozole Tablets
Phase 3UNKNOWN 2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Breast Cancer
Conditions
Advanced Breast Cancer
Trial Timeline
Jul 19, 2019 → Dec 30, 2023
NCT ID
NCT03966898About SHR6390 Tablets + Placebo Tablets + Letrozole or Anastrozole Tablets
SHR6390 Tablets + Placebo Tablets + Letrozole or Anastrozole Tablets is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Advanced Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03966898. Target conditions include Advanced Breast Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Breast Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03966898 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Advanced Breast Cancer